DBV Technologies | DBVT - Betriebsergebnis

Aktienkurs
22.20
Täglich Wechseln
-0.59 -2.59%
Monatlich
4.42%
Jährlich
395.95%
Q1 Prognose
20.46




Betriebsergebnis Veränderung Datum
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
Alnylam Pharmaceuticals USD 29.4M 59.36M 2025-12
Amarin USD -1.7M 8.47M 2025-09
BioCryst Pharmaceuticals USD -2.54M 10.23M 2024-12
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
DBV Technologies USD -34.28M 6.83M 2025-09
Esperion Therapeutics USD -16.03M 18.6M 2024-09
Galectin Therapeutics USD -11.29M 1.64M 2024-06
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
Incyte USD 383.88M 47.43M 2025-12
Insmed USD -249.71M 11.64M 2025-12
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
PTC Therapeutics USD -81.62M 85.11M 2025-12
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
United Therapeutics USD -14.6M 403.9M 2025-12